Insmed to Host First Quarter 2023 Financial Results Conference Call on Thursday, May 4, 2023

Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM) announced it will release its first quarter 2023 financial results on May 4, 2023. A conference call for investors will be held at 8:30 a.m. ET on the same day to discuss the results and provide a business update.

Participants can join the call by dialing (833) 470-1428 for U.S. calls or (929) 526-1599 for international calls, using access code 468531. The call will also be available via a live webcast on Insmed's website.

A replay will be accessible after the call, lasting until June 3, 2023. Insmed is dedicated to treating serious and rare diseases with its approved therapies and an expanding pipeline.

BRIDGEWATER, N.J., April 20, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first quarter 2023 financial results on Thursday, May 4, 2023.

Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, May 4, 2023, to discuss the financial results and provide a business update.

Shareholders and other interested parties may participate in the conference call by dialing (833) 470-1428 (U.S.) or (929) 526-1599 (international) and referencing access code 468531. The call will also be webcast live on the company's website at www.insmed.com.

A replay of the conference call will be accessible approximately 30 minutes after its completion through June 3, 2023, by dialing (866) 813-9403 (U.S.) or (+44) 204-525-0658 (international) and referencing access code 281829. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at www.insmed.com.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com.

Contact:

Investors:

Bryan Dunn
Executive Director, Investor Relations
Insmed
(646) 812-4030
bryan.dunn@insmed.com

Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com

Media:

Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-host-first-quarter-2023-financial-results-conference-call-on-thursday-may-4-2023-301802291.html

SOURCE Insmed Incorporated

FAQ

When will Insmed release its first quarter 2023 financial results?

Insmed will release its first quarter 2023 financial results on May 4, 2023.

What time is Insmed's conference call for investors?

The conference call for investors will take place at 8:30 a.m. ET on May 4, 2023.

How can I participate in Insmed's conference call?

Participants can dial (833) 470-1428 for U.S. calls or (929) 526-1599 for international calls, referencing access code 468531.

Where can I find the webcast for Insmed's financial results call?

The conference call will be webcast live on Insmed's website.

Is there a replay available for Insmed's conference call?

Yes, a replay will be available approximately 30 minutes after the call and can be accessed until June 3, 2023.